Publications by authors named "Luc-Mathieu Fornecker"

Claim this Profile
O
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.
Carmen Martínez, Irma Khvedelidze, Mathilde Fekom, Benedicte Deau Fischer, Amira Marouf, Luc-Mathieu Fornecker

Bone Marrow Transplant· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.
Cédric Rossi, Guillaume Manson, Amira Marouf, Aurélie Cabannes-Hamy, Emmanuelle Nicolas-Virelizier, Luc-Mathieu Fornecker

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.
Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, Luc-Mathieu Fornecker, Emmanuelle Ferrant

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Acute myeloid leukemia with mutated RUNX1 at the university hospitals of Strasbourg].
Baptiste Panaget, Laurent Mauvieux, Laurent Miguet, Luc-Mathieu Fornecker, Bruno Lioure

Ann Biol Clin (Paris)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Luc Mathieu Fornecker

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, Valerie Rouille, Beatrice Mahe, Luc Mathieu Fornecker

Lancet Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
Sylvain P Chantepie, Sylvain Garciaz, Emmanuelle Tchernonog, Frederic Peyrade, Marie-Virginie Larcher, Luc-Mathieu Fornecker

Am J Hematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.
Michael Loschi, Raphael Porcher, Fiorenza Barraco, Louis Terriou, Mohamad Mohty, Luc Mathieu Fornecker

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Vincent Ribrag, Serge Koscielny, Jacques Bosq, Thibaut Leguay, Olivier Casasnovas, Luc-Mathieu Fornecker

Lancet· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis